
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is poised for strong growth in the second half of 2026 with expected FDA approvals, new products, and positive clinical trial data. Despite potential negative impacts and external factors, analysts have raised the price target and maintain a Buy rating. The company's focus on oncology and plans to separate its Orthopaedics business, along with a commitment to sustainability and innovative treatments, showcase their dedication to maintaining market share and driving growth in key therapeutic areas.
Bears say
Johnson & Johnson is facing several challenges in their pharmaceutical division, including LOE for key drugs, uncertain uptake of pipeline products, and concerns around drug pricing. Additionally, while their MedTech division has potential for growth, there are hurdles in achieving this, such as the success of their surgical robotics and potential M&A challenges. Furthermore, ongoing litigations, including talc lawsuits, could disrupt business operations.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares